Dr. Ori Ben-Yehuda joins CardioVascular BioTherapeutics, Inc. as Chief Medical Officer
DALLAS, Oct. 2, 2018 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. ("CVBT" or the "Company") is pleased to welcome Ori Ben-Yehuda, MD, FACC as our new Chief Medical Officer (CMO). "Dr. Ben-Yehuda brings leading edge skills and demonstrated drug development success to the Company. He will guide our clinical team in our current and future development stage research programs," CVBT's Chairman and CEO, Calvin Wallen, III, stated.
CVBT's Executive Vice President for R & D, Laurence R. Meyerson, PhD, commented "Dr. Ben-Yehuda is a key and timely addition to our R & D team as CMO. Ori will be instrumental in leading the clinical research effort for our coronary artery disease and peripheral artery disease programs, as well as others. He will also assist in transitioning our preclinical programs to IND stage projects." Dr. Ben-Yehuda is additionally the Executive Director of the Cardiovascular Research Foundation Clinical Trials Center and is the Deputy Editor of Structural Heart: The Journal of the Heart and the Editor-in-Chief of Coronary Artery Disease. Prior to joining CRF, Dr. Ben-Yehuda was Vice President,Cardiovascular Clinical Research at Gilead Sciences. Prior to that, he was Professor of Clinical Medicine at the University of California, San Diego (UCSD) and the Director of the Coronary Care Unit at UCSD Medical Center. Dr. Ben-Yehuda received his medical degree from the Sackler School of Medicine at Tel Aviv University in Israel and completed a cardiovascular medicine fellowship at the University of California, San Diego.
About CardioVascular BioTherapeutics
CardioVascular BioTherapeutics, Inc. is a biopharmaceutical company developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease, peripheral artery disease, erectile dysfunction, stroke, and spinal disc disease. The active pharmaceutical ingredient (API) in our drug candidates is FGF-1, a human protein that stimulates the growth of new blood vessels, thereby increasing the blood supply to ischemic organs and tissues.
Forward-Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward-looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage, and financial performance. Additionally, until CVBT is cash flow positive from operations, the Company is dependent upon raising capital to fund its operations and meet its obligations as they come due. There can be no assurance that CVBT will be able to raise the necessary capital when needed.
SOURCE CardioVascular BioTherapeutics, Inc.
Share this article